Department of Biomedical Sciences and Engineering, National Central University, Taoyuan 320317, Taiwan.
Department of Life Sciences, National Central University, Taoyuan 320317, Taiwan.
Biomolecules. 2021 Nov 8;11(11):1648. doi: 10.3390/biom11111648.
Immune checkpoint inhibitors are a promising therapy for the treatment of cancers, including melanoma, that improved benefit clinical outcomes. However, a subset of melanoma patients do not respond or acquire resistance to immunotherapy, which limits their clinical applicability. Recent studies have explored the reasons related to the resistance of melanoma to immune checkpoint inhibitors. Of note, miRNAs are the regulators of not only cancer progression but also of the response between cancer cells and immune cells. Investigation of miRNA functions within the tumor microenvironment have suggested that miRNAs could be considered as key partners in immunotherapy. Here, we reviewed the known mechanism by which melanoma induces resistance to immunotherapy and the role of miRNAs in immune responses and the microenvironment.
免疫检查点抑制剂是一种有前途的癌症治疗方法，包括黑色素瘤，可改善临床获益。然而，一部分黑色素瘤患者对免疫疗法无反应或产生耐药性，限制了其临床应用。最近的研究探讨了与黑色素瘤对免疫检查点抑制剂耐药相关的原因。值得注意的是，miRNA 不仅是癌症进展的调节剂，也是癌细胞与免疫细胞之间相互作用的调节剂。miRNA 在肿瘤微环境中的功能研究表明，miRNA 可以被认为是免疫治疗的关键伙伴。在这里，我们综述了黑色素瘤诱导免疫治疗耐药的已知机制以及 miRNA 在免疫反应和微环境中的作用。
